Navigation Links
TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
Date:8/27/2007

new CNS therapies for chronic pain, including migraine and neuropathic pain; and cognitive disorders, including cognitive impairment associated with schizophrenia and Alzheimer's disease. Further information is available at http://www.torreypinestherapeutics.com.

This press release contains forward-looking statements or predictions. Such forward-looking statements include, but are not limited to, statements regarding the anticipated timing for reporting clinical trial results for tezampanel, the potential for tezampanel as a treatment for migraine and other pain indications and the potential of TorreyPines Therapeutics' product candidates to treat certain diseases and disorders. Such statements are subject to numerous factors, risks, and uncertainties that may cause actual events or results to differ materially from the combined company's current expectations. Statements regarding TorreyPines Therapeutics' product candidates are subject to risks and uncertainties regarding development, regulatory approval and commercialization, including whether any preclinical studies or clinical trials, either ongoing or conducted in the future, will prove successful, and if successful, whether the results can be replicated; whether safety and efficacy profiles of any of its drug candidates will be established, or if established, will remain the same, be better or worse in future clinical trials, if any; whether pre-clinical results will be substantiated by ongoing or future clinical trials, if any, or whether any of its drug candidates will be able to improve the signs or symptoms of their respective clinical indication; whether any of its drug candidates will support an NDA filing, will be approved by the FDA or its equivalent, or if approved, will prove competitive in the market; or whether the necessary financing to support its drug development programs will be available. Actual results may differ materi
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)...  Synapse Biomedical Inc. ( www.synapsebiomedical.com ) announced ... post-approval study of its NeuRx DPS® System for ... the FDA enrollment requirement was implanted over a ... NeuRx DPS®, which is the only medical device ... is a humanitarian device that obtained approval at ...
(Date:9/30/2014)... , Sept. 30, 2014 EXECUTIVE SUMMARY ... Industry Outlook to 2017 - Increasing Demand from ... analysis of the industry past, present and future ... Canada market with outlook to ... dietary supplements. Additionally the sub-segments of the industry, ...
(Date:9/30/2014)... DURHAM, N.C. , Sept. 30, 2014 /PRNewswire/ ... that Viztek LLC (Viztek), a leading provider of ... licensed HeartIT,s zero footprint patent portfolio. The licensed ... to provide access to diagnostic-quality medical images in ... part of the agreement, Viztek and its Subsidiaries ...
Breaking Medicine Technology:Synapse Biomedical Announces the Early Completion of Enrollment in the FDA Post Approval Study for ALS Patients 2Synapse Biomedical Announces the Early Completion of Enrollment in the FDA Post Approval Study for ALS Patients 3North America Nutraceuticals Industry Outlook to 2017- Increasing Demand from Ageing Population to Drive Growth 2North America Nutraceuticals Industry Outlook to 2017- Increasing Demand from Ageing Population to Drive Growth 3
... 2011 Varian Medical Systems (NYSE: ... order from U.S. Customs and Border Protection (CBP) for multiple ... represents the company,s largest single order for Varian,s IntellX gantry ... border, scanning vehicles for both border security and manifest verification ...
... PITTSBURGH, Jan. 27, 2011 Mylan Inc. (Nasdaq: ... subsidiary Matrix Laboratories Limited has signed an agreement ... manufacture, market and distribute a generic version of ... pending its regulatory approval for the treatment of ...
Cached Medicine Technology:Varian Medical Systems' Security and Inspection Products Group Receives Largest Single Order for IntellX Systems 2Mylan's Matrix Obtains License for Promising HIV/AIDS Treatment 2
(Date:9/30/2014)... HealthDay Reporter , MONDAY, Sept. ... broad-spectrum antibiotics before the age of 2 may face ... new research suggests. Broad-spectrum antibiotics target a larger ... study. "It is a reason to think about ... picking," said lead researcher Dr. Charles Bailey, attending physician ...
(Date:9/30/2014)... Edward D. Buckingham, M.D., owner of ... approved to be a director of a fellowship for ... (AAFPRS) fellowship program. The announcement came last week from ... The Educational and Research Foundation for the AAFPRS fellowship ... the finest postgraduate program in the world for the ...
(Date:9/30/2014)... Gummy teeth treatment expert, Dr. ... dark gums. Dark gums are usually considered a cosmetic ... about their smiles. Dr. Farnoosh has pioneered a procedure ... of the few dental professionals nationwide offering black ... leaders, high-ranking officials and patients from all over the ...
(Date:9/30/2014)... HealthDay Reporter TUESDAY, Sept. ... supplements won,t prevent the return of a common type of ... In fact, 64.1 percent of those taking fish oil for ... over the course of 16 months, compared to 63.2 ... did not reduce the twin ills of inflammation or oxidative ...
(Date:9/30/2014)... 30, 2014 Lea Blackwell, M.D., a ... cancer patients a new, more practical and comfortable option ... undergo mastectomies, biopsies and lumpectomy surgeries use special bras ... after seeing her patients describe the bra as scratchy, ... a new bra in her spare time. , ...
Breaking Medicine News(10 mins):Health News:Antibiotic Use Before Age 2 Might Raise Obesity Risk, Study Says 2Health News:Antibiotic Use Before Age 2 Might Raise Obesity Risk, Study Says 3Health News:Dr. Edward Buckingham Approved to be Fellowship Director for Facial Plastic Surgery 2Health News:Dr. Edward Buckingham Approved to be Fellowship Director for Facial Plastic Surgery 3Health News:Gummy Smile Dentist, Dr. Alex Farnoosh, is Now Offering Gum Depigmentation for Dark Gums 2Health News:Fish Oil Supplements Have Little Effect on Irregular Heartbeat: Study 2Health News:Fish Oil Supplements Have Little Effect on Irregular Heartbeat: Study 3Health News:Surgeon Creates New Bra for Breast Cancer Patients, Post-Surgery 2Health News:Surgeon Creates New Bra for Breast Cancer Patients, Post-Surgery 3
... many as 10% of people of Asian descent, operations ... mathematical models that verified the cost effectiveness of hepatitis ... vaccinate millions of Asian and Pacific Islander adults in ... to a paper in a journal of the Institute ...
... (HealthDay News) -- In the days after they start ... bupropion or venlafaxine, nursing home residents are at significantly ... Researchers found the increased risk for falls also ... their current prescription. "Our results identify the days ...
... increasing globally. Requiring two doctors to agree that a ... baby, rather than just needing one opinion, providing internal ... and seeking support from local opinion leaders may reduce ... relaxation classes for women with a fear or anxiety ...
... spoils of war for returning veterans may include addictions, ... witnessed. Now a University of Houston joint study ... Development service looks to address these issues through the ... College of Social Work (GCSW) joins Baylor College of ...
... News) -- Depression rates are higher in richer countries ... who compared socioeconomic conditions with depression. About 121 ... quality of life by affecting their ability to ... suicide and causes 850,000 deaths every year. Detailed ...
... 26 (HealthDay News) -- A person,s brain works hard to ... people,s shoes, no matter how different they may be, a ... California found people automatically attempt to empathize -- even with ... people must use two separate regions of their brain. ...
Cached Medicine News:Health News:INFORMS study: OR models of hepatitis B prove decisive in treating millions in US, China 2Health News:INFORMS study: OR models of hepatitis B prove decisive in treating millions in US, China 3Health News:Certain Antidepressants Linked to Falls in Nursing Homes 2Health News:Local efforts can stem the increasing unnecessary cesarean sections 2Health News:Returning vets' alcohol abuse addressed in virtual reality study 2Health News:Depression Higher in Wealthier Nations 2Health News:Human Brains Wired to Empathize, Study Finds 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: